Bausch Health Presents Amiselimod Phase 2 Data For Ulcerative Colitis At DDW 2024 And Rifaximin Analysis At ILC 2024
Portfolio Pulse from Benzinga Newsdesk
Bausch Health presented Phase 2 data for Amiselimod in treating ulcerative colitis at DDW 2024 and analysis of Rifaximin at ILC 2024.
June 14, 2024 | 6:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bausch Health presented promising Phase 2 data for Amiselimod in treating ulcerative colitis at DDW 2024 and analysis of Rifaximin at ILC 2024, which could positively impact the stock price.
The presentation of positive Phase 2 data for Amiselimod and analysis of Rifaximin at major conferences could boost investor confidence and positively impact Bausch Health's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100